Compounds > xaliproden
Page last updated: 2024-09-03

xaliproden and Disease Models, Animal

xaliproden has been researched along with Disease Models, Animal in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV1
Joodi, G; Kleger, A; Mäder, K; Neumann, M; Niess, JH; Porzner, M; Seufferlein, T; von Boyen, G; Walldorf, J; Weissbach, J1
Ahmed, CM; Biswal, MR; Han, P; Ildefonso, CJ; Lewin, AS; Li, H1
Müller, T; Porzner, M; Seufferlein, T1
Confort-Gouny, S; Cozzone, PJ; Fournier, J; Keane, P; Le Fur, Y; Lemaire, L; Ponthus, C; Vion-Dury, J1

Reviews

1 review(s) available for xaliproden and Disease Models, Animal

ArticleYear
SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:11

    Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Naphthalenes; Neurodegenerative Diseases; Neuroprotective Agents; Pyridines

2009

Other Studies

4 other study(ies) available for xaliproden and Disease Models, Animal

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection

2020
The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis.
    Inflammatory bowel diseases, 2022, 03-02, Volume: 28, Issue:3

    Topics: Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Epithelial Cells; Humans; Intestinal Mucosa; Mice; Naphthalenes; Neuroglia; Pyridines; Serotonin 5-HT1 Receptor Agonists

2022
Repurposing an orally available drug for the treatment of geographic atrophy.
    Molecular vision, 2016, Volume: 22

    Topics: Administration, Oral; Animals; Cell Line; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Repositioning; Electric Impedance; Electroretinography; Enzyme-Linked Immunosorbent Assay; Geographic Atrophy; Humans; Metallothionein; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naphthalenes; Pyridines; Real-Time Polymerase Chain Reaction; Retina; Retinal Pigment Epithelium; Serotonin 5-HT1 Receptor Agonists; Tomography, Optical Coherence; Zonula Occludens-1 Protein

2016
Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats.
    Investigative radiology, 2002, Volume: 37, Issue:6

    Topics: Alzheimer Disease; Animals; Brain; Choline O-Acetyltransferase; Disease Models, Animal; Enzyme Inhibitors; Magnetic Resonance Imaging; Male; Naphthalenes; Neuroprotective Agents; Pyridines; Rats; Rats, Sprague-Dawley; Time Factors; Vincristine

2002